Molecular mechanisms of DNA damage by PAHs

PAHs 损伤 DNA 的分子机制

基本信息

  • 批准号:
    8104007
  • 负责人:
  • 金额:
    $ 29.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-01 至 2012-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Molecular mechanisms of DNA damage by PAHs. Polycyclic aromatic hydrocarbons (PAHs) can be a activated to reactive intermediates capable of inducing DNA damage by three major pathways. First, cytochromes P450 (P450) 1A1 and CYP1B1 can convert frans-dihydrodiols to (+)-a/tf/-diol-epoxides, which yield primarily a stable (+)-anft-fr"ans-N2-2'-deoxyguanosine (dGuo) adduct. Second, CYP peroxidase can convert the parent PAH to radical cations that form depurinating N7- and C8-guanine (Gua) and N7-adenine (Ade) adducts. Third, AKRs can convert trans-dihydrodiols to o-quinones, which redox cycle to generate reactive oxygen species (ROS). The ROS can directly modify DNA to form 7,8-dihydro-8-oxo-2'- deoxyguanosine (8-oxo-dGuo) as well as inducing the formation of lipid hydroperoxides. Lipid hydroperoxides undergo homolytic decomposition to form the bifunctional electrophile 4-oxo-2-nonenal, which then covalently modify DNA to form a heptanone-etheno-dGuo (HsdGuo)-adduct. We propose to use the ubiquitous environmental carcinogen benzo[a]pyrene (B[a]P) as a model PAH to explore the role of environmental exposure to PAHs in the induction of oxidative stress and formation of DNA-adducts. We have developed a stable isotope dilution liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) method for the specific analysis of (+)-anf/-frans-B[a]P-7,8,9,10-tetrahydro-7,8- diol-9,10-epoxide-N2-dGuo-adduct and quantified the formation of this adduct in four different human lung- derived cell lines. These studies have unexpectedly revealed that up-regulation of P450s 1A1 and 1B1 has a protective effect on DNA damage. We now propose to explore the molecular basis of this exciting new finding. Immunoaffinity stable isotope dilution LC-MRM/MS methodology has also recently revealed that lipid oxidation-derived HedGuo is present in the urine of subjects exposed to high levels of B[a]P through smoking. These studies will be extended to a B[a]P-exposed mouse model in which the B[a]P-derived urinary metabolites and DNA-adducts will be quantified together with urinary lipid oxidation products and HedGuo. Translational research will be conducted by monitoring the exposure of human populations to B[a]P through analysis of urinary B[a]P metabolites. The effects of this exposure will be assessed by monitoring urinary B[a]P-DNA-adducts, HedGuo, and oxidized lipids in the same subjects. We propose to address the following hypotheses: (1) P450 1A1 and 1B1 protect against DNA damage by facilitating removal of B[a]P metabolites through phase II enzymes. (2) Transport into the nucleus is an important determinant of DNA damage. (3) Analysis of oxidized lipids and B[a]P metabolites will define the relationship between oxidative stress and B[a]P exposure. (4) Quantitative analysis of urinary B[a]P- and a lipid oxidation-derived DNA-adducts will provide insight into the amount of DNA damage that has occurred in an animal model and in human populations exposed to B[a]P. The proposed research will be conducted under four specific aims. Aim 1. To analyze lipid oxidation- and B[a]P-derived DNA-adducts in cellular models of impaired nuclear transport. Aim 2. To develop stable isotope dilution LC-electron capture atmospheric pressure chemical ionization/MRM/MS and immunoaffinity LC-MRM/MS methodology for analysis of urinary B[a]P metabolites and B[a]P-derived DNA-adducts, respectively. Aim 3. To quantify urinary oxidized lipids, HedGuo, B[a]P metabolites, and B[a]P-derived DNA-adducts in a mouse model exposed to B[a]P. Aim 4. To quantify urinary oxidized lipids, HedGuo, B[a]P metabolites, and B[a]P-derived DNA-adducts in smoking and non-smoking human populations exposed to environmental B[a]P. Successful completion of the proposed research will permit provide a new approach and novel methodology for determining the inter-individual risk factors for DNA damage, which result from environmental exposure to B[a]P.
描述(由申请人提供):多环芳烃DNA损伤的分子机制。多环芳烃(PAHs)可以通过三种主要途径被激活为能够诱导DNA损伤的活性中间体。首先,细胞色素P450 (P450) 1A1和CYP1B1可以将反式二氢二醇转化为(+)-a/tf/-二醇环氧化物,这主要产生稳定的(+)-抗“ans-N2-2”-脱氧鸟苷(dGuo)加合物。其次,CYP过氧化物酶可以将母体多环芳烃转化为自由基阳离子,形成去纯化的N7-和c8 -鸟嘌呤(Gua)和N7-腺嘌呤(Ade)加合物。第三,akr可以将反式二氢二醇转化为邻醌,并通过氧化还原循环生成活性氧(ROS)。ROS可以直接修饰DNA形成7,8-二氢-8-氧-2'-脱氧鸟苷(8-氧- dguo),并诱导脂质氢过氧化物的形成。脂质氢过氧化物经过均解分解形成双功能亲电试剂4-氧-2-壬烯醛,然后共价修饰DNA形成庚酮-乙烯- dguo (HsdGuo)-加合物。我们建议使用普遍存在的环境致癌物苯并[a]芘(B[a]P)作为多环芳烃模型,探讨多环芳烃环境暴露在诱导氧化应激和dna加合物形成中的作用。我们建立了一种稳定同位素稀释液相色谱-多重反应监测/质谱(LC-MRM/MS)方法,用于特异性分析(+)-anf/- trans - b [a] p -7,8,9,10-四氢-7,8-二醇-9,10-环氧化物- n2 - dguo -加合物,并定量了该加合物在四种不同的人肺源性细胞系中的形成。这些研究意外地揭示了P450s 1A1和1B1的上调对DNA损伤具有保护作用。我们现在提议探索这一令人兴奋的新发现的分子基础。免疫亲和稳定同位素稀释LC-MRM/MS方法最近也显示,通过吸烟暴露于高水平B[a]P的受试者的尿液中存在脂质氧化衍生的黑果。这些研究将扩展到B[a] p暴露小鼠模型,其中B[a] p衍生的尿液代谢物和dna加合物将与尿脂氧化产物和黑果一起被量化。转化研究将通过分析尿液B[a]P代谢物来监测人群对B[a]P的暴露情况。这种暴露的影响将通过监测尿B[a] p - dna加合物、黑果和氧化脂质来评估。我们提出以下假设:(1)P450 1A1和1B1通过II期酶促进B[a]P代谢物的去除来保护DNA免受损伤。(2)转运进入细胞核是DNA损伤的重要决定因素。(3)氧化脂质和B[a]P代谢产物的分析将明确氧化应激与B[a]P暴露之间的关系。(4)对尿中B[a]P-和脂质氧化衍生的DNA加合物进行定量分析,将有助于了解在动物模型和暴露于B[a]P的人群中发生的DNA损伤量。拟议的研究将根据四个具体目标进行。目的1。分析核运输受损细胞模型中脂质氧化和B[a] p来源的dna加合物。目标2。建立稳定同位素稀释lc -电子捕获常压化学电离/MRM/MS和免疫亲和LC-MRM/MS方法,分别用于分析尿液B[a]P代谢物和B[a]P衍生dna加合物。目标3。在暴露于B[a]P的小鼠模型中,定量测定尿氧化脂质、黑果、B[a]P代谢产物和B[a]P来源的dna加合物。目标4。吸烟和不吸烟人群暴露于环境中B[a]P代谢产物和B[a]P来源的dna加合物的定量分析。该研究的成功完成将为确定环境暴露导致的DNA损伤的个体间风险因素提供一种新的方法和方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ian Alexander Blair其他文献

Ian Alexander Blair的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ian Alexander Blair', 18)}}的其他基金

Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10337249
  • 财政年份:
    2020
  • 资助金额:
    $ 29.25万
  • 项目类别:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10115684
  • 财政年份:
    2020
  • 资助金额:
    $ 29.25万
  • 项目类别:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10565951
  • 财政年份:
    2020
  • 资助金额:
    $ 29.25万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10356088
  • 财政年份:
    2020
  • 资助金额:
    $ 29.25万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10582596
  • 财政年份:
    2020
  • 资助金额:
    $ 29.25万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10117295
  • 财政年份:
    2020
  • 资助金额:
    $ 29.25万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    9530878
  • 财政年份:
    2014
  • 资助金额:
    $ 29.25万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    9041609
  • 财政年份:
    2014
  • 资助金额:
    $ 29.25万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    8651082
  • 财政年份:
    2014
  • 资助金额:
    $ 29.25万
  • 项目类别:
Core N: MOLECULAR PROFILING
核心 N:分子谱分析
  • 批准号:
    8126787
  • 财政年份:
    2012
  • 资助金额:
    $ 29.25万
  • 项目类别:

相似海外基金

Neurotoxicity of deoxyadenosine and neuroprotective effects of adenosine deaminase
脱氧腺苷的神经毒性和腺苷脱氨酶的神经保护作用
  • 批准号:
    16K08923
  • 财政年份:
    2016
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification and characterization of methyl-deoxyadenosine in the eukaryotic genome.
真核基因组中甲基脱氧腺苷的鉴定和表征。
  • 批准号:
    BB/M022994/1
  • 财政年份:
    2015
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Research Grant
SYNTHESIS OF [6 15N] 2 DEOXYADENOSINE
[6 15N] 2 脱氧腺苷的合成
  • 批准号:
    6251998
  • 财政年份:
    1997
  • 资助金额:
    $ 29.25万
  • 项目类别:
RECEPTORS FOR ADENINE AND DEOXYADENOSINE
腺嘌呤和脱氧腺苷受体
  • 批准号:
    2444437
  • 财政年份:
    1996
  • 资助金额:
    $ 29.25万
  • 项目类别:
MECHANISM OF CYTOTOXICITY OF DEOXYADENOSINE AND ANALOGS
脱氧腺苷及其类似物的细胞毒性机制
  • 批准号:
    3178061
  • 财政年份:
    1986
  • 资助金额:
    $ 29.25万
  • 项目类别:
MECHANISM OF CYTOTOXICITY OF DEOXYADENOSINE AND ANALOGS
脱氧腺苷及其类似物的细胞毒性机制
  • 批准号:
    3178065
  • 财政年份:
    1986
  • 资助金额:
    $ 29.25万
  • 项目类别:
MECHANISM OF CYTOTOXICITY OF DEOXYADENOSINE AND ANALOGS
脱氧腺苷及其类似物的细胞毒性机制
  • 批准号:
    3178066
  • 财政年份:
    1986
  • 资助金额:
    $ 29.25万
  • 项目类别:
SYNTHESIS OF [6 15N] 2 DEOXYADENOSINE
[6 15N] 2 脱氧腺苷的合成
  • 批准号:
    3723157
  • 财政年份:
  • 资助金额:
    $ 29.25万
  • 项目类别:
MOLECULAR CLONING OF BACTERIAL DEOXYCYTIDINE/DEOXYADENOSINE KINASE
细菌脱氧胞苷/脱氧腺苷激酶的分子克隆
  • 批准号:
    3935271
  • 财政年份:
  • 资助金额:
    $ 29.25万
  • 项目类别:
MOLECULAR CLONING OF BACTERIAL DEOXYCYTIDINE/DEOXYADENOSINE KINASE
细菌脱氧胞苷/脱氧腺苷激酶的分子克隆
  • 批准号:
    3914170
  • 财政年份:
  • 资助金额:
    $ 29.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了